Alzheimer's patients with the exact same diagnosis can have completely different patterns of brain cell destruction.
April 24, 2026
Original Paper
Cell-projected Phenotypes Link Transcriptional and Phenotypic Heterogeneity in Alzheimer’s Disease
SSRN · 6615879
The Takeaway
Medical professionals often treat Alzheimer's as a single, uniform disease with a predictable progression. A new analysis tool revealed that the transcriptional state of individual cells varies wildly even among donors with the same symptoms. Some patients show high levels of cognitive decline but relatively healthy-looking brain cells, while others show the reverse. This cellular mismatch explains why drugs that work for one person fail completely for another. It suggests that we need personalized treatments tailored to a patient's specific cellular profile rather than a one-size-fits-all approach.
From the abstract
Single-cell transcriptomics analysis typically uses binary case-control labels that obscure heterogeneity within and between individuals. Here we introduce Cell-Projected Phenotypes (CPP), a framework that leverages disease-associated single-cell transcriptional neighborhoods from large cohorts to project donor-level phenotypes onto individual cells, translating ‘bulk’ phenotypes into continuous cell-level disease scores, ultimately aggregated into individual-level continuous phenotypic scores.